INFI - Infinity Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-15.66M

Cash

17.75M

Avg Qtr Burn

-9.721M

Short % of Float

2.69%

Insider Ownership

2.36%

Institutional Own.

23.49%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Pembrolizumab Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma, Melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + etrumadenant + Doxil® Details Breast cancer, Triple-negative breast cancer , Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Nivolumab Details Urothelial cancer, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Nivolumab Details Solid tumor/s, Head and neck squamous cell carcinoma, Melanoma, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.